156 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
CRSP CRISPR Therapeutics AG $50.31 $2.39B N/A
Article Searches
What's in Store for Vertex in 2020 After a Remarkable 2019? http://www.zacks.com/stock/news/765734/whats-in-store-for-vertex-in-2020-after-a-remarkable-2019?cid=CS-ZC-FT-analyst_blog|rank_focused-765734 Feb 14, 2020 - In 2020, Vertex's (VRTX) sales are expected to be primarily driven by Trikafta and higher international revenues.
First CRISPR Gene Editing Trial in Cancer Patients Shows Promising Results https://www.fool.com/investing/2020/02/07/first-crispr-gene-editing-trial-in-cancer-patients.aspx?source=iedfolrf0000001 Feb 07, 2020 - The technique itself appears to be safe and effective in humans.
If You Invested $100 in CRISPR Therapeutics' IPO, This Is How Much Money You'd Have Now https://www.fool.com/investing/2020/02/07/if-you-invested-100-in-crispr-therapeutics-ipo-thi.aspx?source=iedfolrf0000001 Feb 07, 2020 - This gene-editing biotech company rewarded those who invested in its cutting-edge technology.
Vertex (VRTX) Q4 Earnings Beat on Solid CF Product Sales http://www.zacks.com/stock/news/743173/vertex-vrtx-q4-earnings-beat-on-solid-cf-product-sales?cid=CS-ZC-FT-analyst_blog|earnings_article-743173 Jan 31, 2020 - Vertex (VRTX) rides high on earnings and revenue beat in Q4. The company provides solid outlook for 2020 resulting in the shares to go up in after-hours trading.
Can CF Drugs Drive Growth for Vertex (VRTX) in Q4 Earnings? http://www.zacks.com/stock/news/736752/can-cf-drugs-drive-growth-for-vertex-vrtx-in-q4-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-736752 Jan 28, 2020 - On Vertex's (VRTX) fourth-quarter earnings call, investor focus will be on the sales uptake of its CF drugs and the unveiling plans for the newly-approved Trikafta triple combination regimen.
3 Top Biotech Picks for 2020 https://www.fool.com/investing/2020/01/20/3-top-biotech-picks-for-2020.aspx?source=iedfolrf0000001 Jan 20, 2020 - These stocks could thump the broader markets this year.
Why 2020 Should Be the Biggest Year Yet for CRISPR Gene-Editing Stocks https://www.fool.com/investing/2019/12/22/why-2020-should-be-the-biggest-year-yet-for-crispr.aspx?source=iedfolrf0000001 Dec 22, 2019 - More pipeline activity than ever before could usher in a big boom for CRISPR gene-editing stocks next year.
This Start-up Might Be the Next Gene Editing IPO https://www.fool.com/investing/2019/12/19/this-start-up-might-be-the-next-gene-editing-ipo.aspx?source=iedfolrf0000001 Dec 19, 2019 - An early-stage start-up with an improved version of CRISPR gene editing filed to go public. Investors may want to keep an eye on it.
Here's Why Vertex Pharmaceuticals Rose 13.4% in November https://www.fool.com/investing/2019/12/04/heres-why-vertex-pharmaceuticals-rose-134-in-novem.aspx?source=iedfolrf0000001 Dec 04, 2019 - The rare-disease specialist is putting together a respectable end-of-year run.
Biotech Tops in November: Best ETFs & Stocks http://www.zacks.com/stock/news/646838/biotech-tops-in-november-best-etfs-stocks?cid=CS-ZC-FT-etf_news_and_commentary-646838 Nov 29, 2019 - The biotech space of the broad healthcare sector outperformed others in November, courtesy of a series of positive news including study results, regulatory backdrop and deal activities.

Pages: 123456...16

Page 1>